Procaps WP

News

Tallac Therapeutics doses first subject in Phase I/II solid tumour trial

The trial will assess the pharmacokinetics, safety, and the preliminary anti-tumour activity of TAC-001 to treat solid tumours.

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close